profit from every $100 of sales.
$0$100
Gossamer Bio
$10.97-2.40% today
+2,085.3% in 1 year
1-year low $0.381-year high $37.76
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2024 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Gossamer Bio sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $48.5 million in 2025, with -$170 million of profit last year.
SalesProfit
Gossamer Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Gossamer Bio | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Gossamer Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 115 | 48 | |
| – | – | – | – | |
| -219 | -174 | -60 | -163 | |
| -211 | -162 | -40 | -158 | |
| -229 | -180 | -57 | -170 | |
| -2.71 | -1.18 | -0.25 | -0.75 | |
| – | – | – | – | |
| – | – | -52.2% | -336.8% | |
| – | – | -49.3% | -351.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 272 | 312 | 315 | 172 |
| Cash | 112 | 32 | 46 | 38 |
| Total debt | 226 | 212 | 203 | 203 |
| Total liabilities | 260 | 249 | 286 | 295 |
| 12 | 63 | 29 | -123 | |
| 85 | 153 | 226 | 229 | |
| -71.6% | -47.7% | -15.0% | -157.2% | |
| -1,899.3% | -286.5% | -191.7% | 138.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -187 | -159 | -3 | -171 | |
| 0 | – | – | 0 | |
| -188 | -159 | -3 | -171 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 43 | 29 | 21 | 11 |
Valuation
- –
- –
- –
- -0.5×
- 1.4×
- –
- –
- -255.4%
- -253.9%
- 0.0%
Profitability
- 69.1%
- -336.8%
- -351.5%
- -308.7%
- -246.8%
- -95.5%
- 174.9%
- -140.0%
- -247.0%
- 336.0%
Growth
- −57.7%
- –
- −4,840.7%
- –
- +32.2%
Financial health
- –
- -1.25
- 156.7%
- -32.6×
- 2.20
- 2.20
- 0.43
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 888
What analysts expect
- Average price target
- $0.77
- Range
- $0.30 – $1.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 18, 2026 | -0.20 | -0.17 | −17.6% |
| Mar 17, 2026 | -0.21 | -0.20 | −5.0% |
| Nov 5, 2025 | -0.21 | -0.19 | −10.5% |
| Aug 5, 2025 | -0.17 | -0.18 | +5.6% |
| May 15, 2025 | -0.16 | -0.18 | +11.1% |
| Mar 13, 2025 | -0.15 | -0.17 | +11.8% |
| Nov 7, 2024 | -0.14 | -0.18 | +22.2% |
| Aug 12, 2024 | 0.22 | 0.23 | −4.3% |
News
Gossamer Bio submits NDA for seralutinib for pulmonary arterial hypertensionSeeking Alpha · Sep 23, 2026The newest story we have is from Sep 23, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/4Passes 0 of 4. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
–Not enough data
Philip Fisher
44No pass
Peter Lynch
–Not enough data
Joel Greenblatt
–Not enough data
Charlie Munger
39No pass
Terry Smith
40No pass
Questions about Gossamer Bio
Is Gossamer Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 4 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Gossamer Bio AI analysis
What does Gossamer Bio do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is in Biotechnology.
Does Gossamer Bio pay a dividend?
No. Gossamer Bio does not pay a dividend at the moment.
Is Gossamer Bio stock halal?
No. Gossamer Bio does not pass our halal screen: its debt is 302% of its market value, at or above the 33% limit. How we check
How has Gossamer Bio stock done over the past year?
Up 2,085.3% over the past twelve months, to $10.97. It traded between $0.38 and $37.76 and is 70.9% below its high.
Who are Gossamer Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Gossamer Bio's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.